Purpose: The effectiveness of every-three-week administration of darbepoetin alfa in women with chemotherapy-associated anemia was evaluated. Methods: Women receiving chemotherapy for gynecological ...

Please provide your email address to receive an email when new articles are posted on . Vadadustat demonstrated the efficacy and cardiovascular safety for the treatment of anemia in adult patients ...

Fixed-Dose Phosphate Binder Schedules May Be Less than Ideal Researchers confirmed higher dose conversion ratios in Taiwanese patients with stable hemoglobin. For Asian hemodialysis (HD) patients with ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Darbepoetin alfa did not decrease the risk for death, ...

The results of the RED-HF trial have been reported in the New England Journal of Medicine. In the RED-HF study, clinical outcomes were compared for the erythropoiesis-stimulating agent (ESA) ...

Aug. 23, 2002 —The erythropoietin analogue darbepoetin alfa reduced the need for transfusions, increased hemoglobin concentrations, and decreased fatigue in patients with lung cancer, according to the ...

Find out how to take Darbepoetin Alfa (drug) and its dose. Describes the best time to take the drug and precautions if any that should be followed. We recommend consulting your doctor to verify the ...

In a real-world study, UPCR decreased when darbepoetin alfa dose exceeded 60 μg in patients with diabetic kidney disease. Darbepoetin alfa treatment is associated with proteinuria lowering in a ...

HYDERABAD, INDIA--(Marketwired - Jun 18, 2014) - The Hetero Group, one of the largest manufacturers and suppliers of Active Pharmaceutical Ingredients (APIs) to the Indian pharmaceutical industry, ...

Review the side-effects of Darbepoetin Alfa as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority ...

Darbepoetin alfa (Aranesp ®, Amgen) is a novel erythropoiesis-stimulating protein with a serum half-life longer than recombinant human erythropoietin (Epo), used in the treatment of cancer-associated ...